Chief Financial Officer Robert Stefanovich of Cryoport, Inc. (NASDAQ: CYRX) sold a total of 41,443 shares of the company’s common stock in two separate transactions executed on March 12 and March 16, 2026, for aggregate proceeds of approximately $322,329.
Details of the trades show that on March 12 Stefanovich sold 38,700 shares at a weighted average price of $7.7619, generating proceeds of $300,385. The reported trade prices in that block ranged between $7.725 and $7.83. On March 16 he sold an additional 2,743 shares at $8.00 per share, yielding $21,944.
Those dispositions occurred alongside other equity-related activity by Stefanovich. On the same day as the March 16 sale he exercised stock options to acquire 87,188 shares at an exercise price of $1.87, for a total exercise value of $163,041. He also acquired 27,413 restricted stock rights on March 14 and holds 82,240 stock options, according to the disclosed filings.
Market context for these moves includes Cryoport’s current share price trading at $8.00 and a reported market capitalization near $399 million. An InvestingPro analysis cited in company disclosures characterizes the stock as appearing overvalued at current levels, and an InvestingPro Tip highlights elevated price volatility with a beta of 1.74.
The insider transactions and awards follow Cryoport’s fourth-quarter 2025 financial results. Revenue for the quarter came in at $45.45 million, ahead of the $42.93 million consensus estimate and representing a 5.87% positive surprise. At the same time, reported earnings per share were -$0.27, missing the expected -$0.21 and constituting a 28.57% shortfall.
Following the earnings release the company’s stock declined in aftermarket trading. The combination of a revenue beat and an EPS miss underscores a mixed quarter for Cryoport and may shape how market participants and analysts assess the company’s near-term prospects.
Summary
Cryoport CFO Robert Stefanovich sold 41,443 shares in two transactions on March 12 and March 16, 2026, collecting roughly $322,329. Concurrently he exercised options to acquire 87,188 shares at $1.87 and received restricted stock rights and additional options. The trades occurred after Cryoport reported Q4 2025 revenue above expectations but EPS below forecasts, and the stock traded lower in aftermarket activity.